Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| calbc:hasCorrelation | |
| skos:definition |
NCI: A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity. Ramucirumab specifically binds to and inhibits VEGFR-2, which may result in an in inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells.,NCI: A substance being studied in the treatment of breast cancer that has come back. It binds to receptors for a protein called vascular endothelial growth factor (VEGF). This keeps VEGF from binding to the receptors and may stop the growth of new blood vessels that tumors need to grow. It is a type of antiangiogenesis agent and a type of monoclonal antibody.
|
| skos:inScheme | |
| skos-xl:prefLabel | |
| skos-xl:altLabel |